ADVERTISEMENT
 |
|
Top BioPharm International News Stories of 2019
|
|
|
The US Senate and the US Pharmacopeial Convention debate the necessity of monographs for biologics.
/ read more /
Dengvaxia is the first FDA-approved vaccine for dengue disease caused by all dengue virus serotypes for individuals ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
/ read more /
The World Health Organization (WHO) has welcomed the launch of a malaria vaccine in a pilot program taking place in Malawi, Africa.
/ read more /
Company to focus on innovation, growth, and productivity with creation of new units.
/ read more /
Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.
/ read more /
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) revealed 22 new projects and funding aimed to advance US biopharmaceutical manufacturing.
/ read more /
|
|
|
SubscribeSubscribers can enjoy each full issue of BioPharm International in print, or via BioPharm apps.
subscription offers
|
|
The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.
/ read more /
The companies will jointly develop and commercialize an investigational bifunctional fusion protein immunotherapy currently in clinical development for cancer treatment.
/ read more /
Catalent’s acquisition of Paragon Bioservices will provide expertise in expanding gene therapy market.
/ read more /
A $1.7-billion acquisition of CDMO Brammer Bio establishes Thermo Fisher Scientific in viral vector manufacturing.
/ read more /
|
|
Top BioPharm International Feature Stories of 2019
|
|
|
New ligands are being developed to meet the separation and purification needs of next-gen biologics.
/ read more /
The commercialization of cell and gene therapies has become a reality, prompting deeper considerations of logistics, technology, and design for manufacturing facilities.
/ read more /
Most extractable and leachable (E&L) studies are based on liquid formulations. This article examines options for E&L studies to evaluate leaching from primary packaging into lyophilized drugs.
/ read more /
This article explores the challenges and potential of next-generation therapeutic antibodies.
/ read more /
Now that the first genetically modified cell therapies are being manufactured, the industry must move beyond “whatever works” to meet growing demand.
/ read more /
Real-time monitoring of product- and process-related impurities remains a challenge.
/ read more /
Research advances have enabled the application of nanotechnology to drug delivery. What does this technology offer in the way of enhancing therapeutic effect?
/ read more /
Sterile filtration is often required for biologics but presents degradation and compatibility challenges.
/ read more /
|
|
|
|
Although downstream efficiency still lags behind upstream, engineering-driven innovation is breaking through boundaries.
/ read more /
A properly designed validation program will detect variation and ensure control based on process risk.
/ read more /
Suppliers address the complexity of supplying disposable components for single-use systems to the global biopharmaceutical manufacturing industry.
/ read more /
Kinetic models can be used to study aggregation and fragmentation to help ensure stability.
/ read more /
As cost and time pressures within biopharma are on the rise, innovative expression systems may offer companies a good opportunity to streamline processes early on.
/ read more /
Optimizing the patient experience and technological advances can positively impact adherence.
/ read more /
Used with perfusion, alternating tangential flow and tangential flow filtration are redefining upstream efficiency.
/ read more /
|
|
|
ON DEMAND WEBCASTS
Optimizing SEC for Analysis of Antibodies and Antibody–Drug Conjugates
On Demand
![]() Learn more
Events
January 15–16, 2020
January 20–21, 2020
February 18–20, 2020
more events
|
|
|
eBook
|
In BioPharm International’s Pharmacopoeia Compliance Series, experts explain the revision process for global and national pharmacopoeias, best practices for monitoring changes, and how to participate in revisions. Other features include FDA warning letters, FDA Form 483s, and essentials for quality risk management.
|
|
|
|
|
| |
